低剂量奥氮平控制抗NMDAR脑炎精神症状的联系分析

doi:10.12092/j.issn.1009-2501.2018.11.016

中国临床药理学与治疗学 ›› 2018, Vol. 23 ›› Issue (11): 1292-1296.doi: 10.12092/j.issn.1009-2501.2018.11.016

低剂量奥氮平控制抗NMDAR脑炎精神症状的联系分析

章晓英¹，王康²，邬莎¹，郭鹏³

¹杭州市第七人民医院神经内科，杭州 310007，浙江； ²浙江大学附属第一医院神经内科，杭州 310006，浙江；³绍兴市中心医院麻醉科，绍兴 312000，浙江

收稿日期:2018-08-23 修回日期:2018-10-11 出版日期:2018-11-26 发布日期:2018-11-22
作者简介:章晓英，女，硕士，主治医师，研究方向：神经系统疾病伴发的精神障碍的研究。
基金资助:
杭州市卫生局课题（2017A48）；浙江省医学会临床科研基金项目（20162YC-86）

Association analysis of low dose olanzapine in controlling mental symptoms of NMDAR encephalitis

ZHANG Xiaoying¹, WANG Kang², WU Sha¹, GUO Peng³

¹Department of Neurology, Hangzhou Seventh People's Hospital, Hanghzou 310007, Zhejiang, China; ²Department of Neurology and Brain Medical Centre, the First Affliated Hospital of Zhejiang University, Hangzhou 310006,Zhejiang, China; ³Department of Anesthesiology, Shaoxing Central Hospital, Shaoxing 312000, Zhejiang, China

Received:2018-08-23 Revised:2018-10-11 Online:2018-11-26 Published:2018-11-22

摘要/Abstract

摘要：

目的: 分析低剂量奥氮平控制抗N-甲基-D-天冬氨酸受体（NMDAR）脑炎精神症状的联系影响。方法: 选取2014年3月至2018年3月间在本院接受治疗的26例抗NMDAR脑炎患者，随机数字表法分成两组，对照组（13例）行常规免疫治疗，观察组（13例）在上述基础上加服低剂量奥氮平，观察患者临床疗效及不良反应状况，治疗前、治疗后1、2周分别采用阴性和阳性症状量表（PANSS）、外显攻击行为量表（MOAS）、护士观察量表（NOSIE）、汉密尔顿焦虑量表（HAMA）及汉密尔顿抑郁量表（HAMD）评判患者精神症状改善情况。结果: 观察组患者总有效率为92.31%，高于对照组的76.92%，差异有统计学意义（P＜0.05）；治疗前，两组患者的MOAS与NOSIE评分比较，差异无统计学意义（P＞0.05）。治疗后1、2周，两组患者的MOAS与NOSIE评分显著低于治疗前，差异均有统计学意义（P＜0.05）。且治疗后1、2周，观察组患者MOAS与NOSIE评分显著低于对照组，差异均有统计学意义（P＜0.05）；治疗前，两组患者的HAMA与HAMD评分比较，差异均无统计学意义（P＞0.05）。治疗后1、2周，两组患者的HAMA与HAMD评分显著低于治疗前，差异均有统计学意义（P＜0.05）。且治疗后1、2周，观察组患者HAMA与HAMD评分显著低于对照组，差异均有统计学意义（P＜0.05）。结论: 持续低剂量奥氮平可显著改善抗NMDAR脑炎患者的精神症状，不良反应较少，但还需要临床更大样本验证。

关键词: 抗N-甲基-D-天冬氨酸受体脑炎, 精神症状, 免疫治疗, 奥氮平

Abstract:

AIM: To analyze the effect of low-dose olanzapine on the association of psychiatric symptoms in anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis. METHODS: Twenty-six adults with anti NMDAR encephalitis treated in our hospital from March 2014 to March 2018 were divided into two groups randomly. The control group (13 cases) was treated with routine immunotherapy. The observation group (13 cases) was given low dose olanzapine on the basis of the above. The clinical efficacy and adverse reactions of the patients were observed. Negative and positive symptom scale (PANSS), explicit aggressive behavior scale (MOAS), nurse observation scale (NOSIE), Hamilton Anxiety Scale (HAMA) and Hamilton Depression Scale (HAMD) were used to evaluate the improvement of mental symptoms in patients 1 and 2 weeks after treatment. RESULTS: The total effective rate was 92.31% in the observation group, which was higher than 76.92% in the control group. The difference was statistically significant (P<0.05). Before treatment, difference of the MOAS and NOSIE scores of the two groups were not statistically different (P>0.05). At 1 and 2 weeks after treatment, the MOAS and NOSIE scores of the two groups were significantly lower than those before treatment, and the difference was statistically significant (P<0.05). The scores of MOAS and NOSIE in the observation group were significantly lower than those in the control group at 1 and 2 weeks after treatment (P<0.05). Before treatment, difference of the HAMA and HAMD scores of the two groups were not statistically significant (P>0.05). At 1 and 2 weeks after treatment, the HAMA and HAMD scores of the two groups were significantly lower than those before treatment, and the difference was statistically significant (P<0.05). At 1 and 2 weeks after treatment, the HAMA and HAMD scores of the observation group were significantly lower than those of the control group (P<0.05). CONCLUSION: Continuous low-dose olanzapine can significantly improve the psychiatric symptoms of patients with anti-NMDAR encephalitis with fewer adverse reactions, but it requires more clinical validation.

Key words: anti N-methyl-D-aspartate receptor encephalitis, psychiatric symptoms, immunotherapy, olanzapine

中图分类号:

章晓英，王康，邬莎，郭鹏. 低剂量奥氮平控制抗NMDAR脑炎精神症状的联系分析[J]. 中国临床药理学与治疗学, 2018, 23(11): 1292-1296.

ZHANG Xiaoying, WANG Kang, WU Sha, GUO Peng. Association analysis of low dose olanzapine in controlling mental symptoms of NMDAR encephalitis[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(11): 1292-1296.

参考文献

［1］Dalmau J, Tüzün E, Wu HY, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma［J］. Ann Neurol, 2007, 61(1): 25-36.
［2］许春伶, 赵伟秦, 李继梅, 等. 抗NMDA受体脑炎一例病例报告［C］// 中华医学会第十三次全国神经病学学术会议论文汇编. 2010, 102-107.
［3］袁晶, 彭斌, 关鸿志, 等. 重症抗N-甲基-D-天冬氨酸受体脑炎35例免疫治疗分析［J］. 中华医学杂志, 2016, 96(13): 1035-1039.
［4］孙振晓, 李景君. 奥氮平联用氟伏沙明致恶性综合征［J］. 药物不良反应杂志, 2016, 18(3): 230-232.
［5］黄小钦, 樊春秋, 叶静. 重症抗 N-甲基-D-天冬氨酸受体脑炎的临床特点及预后分析［J］. 临床神经病学杂志, 2016, 29(2): 101-104.
［6］余天浩, 孙恒斌. 23例抗N-甲基-D-天冬氨酸受体脑炎的临床特点及预后分析［J］. 临床神经病学杂志, 2017, 9(6): 446--449.
［7］卢强, 关鸿志, 任海涛, 等. 应用利妥昔单抗治疗抗N-甲基-D-天冬氨酸受体脑炎三例临床观察［J］. 中华神经科杂志, 2016, 49(1): 30-34.
［8］徐文灯, 贺菲菲, 叶静. 抗N-甲基-D-天冬氨酸受体脑炎51例的预后分析［J］. 中华神经科杂志, 2017, 50(2): 99-102.
［9］贾茜, 郭冬梅, 李小莹, 等. 抗N-甲基-D-天门冬氨酸受体脑炎57例临床分析［J］［J］. 神经疾病与精神卫生, 2016, 16(3): 317-319.
［10］钱颖, 曹秉振. 抗NMDAR脑炎治疗的研究进展［J］. 山东医药, 2017, 19(48): 110-113.
［11］彭彬, 张申起, 董红娟, 等. 抗NMDAR脑炎8例临床特点及文献复习［J］. 卒中与神经疾病, 2018, 3(1): 254-257.
［12］陈云霞, 相春霞, 黄勇华, 等. 抗N-甲基-D--天冬氨酸受体脑炎9例临床分析［J］. 解放军医学杂志, 2016, 41(9): 767-770.
［13］程娜, 黄勇华, 石文磊. 抗NMDAR脑炎二例临床误诊分析［J］. 临床误诊误治, 2016, 29(12): 41-44.
［14］王臖, 邓烨, 耿介立, 等. 抗N-甲基-D-天冬氨酸受体脑炎的临床特点及不同阶段的脑电图表现［J］. 临床内科杂志, 2016, 33(2): 121-123.
［15］冯雪丹, 胡永强, 冯文良, 等. 抗NMDA受体脑炎45例特点和临床转归分析［J］. 脑与神经疾病杂志, 2016, 24(7): 425-429.
［16］耿寒松, 刘荣芹, 边辛丑, 等. 度洛西汀联合奥氮平治疗女性抑郁障碍的对照研究［J］. 河北医药, 2012, 34(13): 2005-2006.
［17］姜颖, 罗昌菊. 抗γ-氨基丁酸B受体抗体脑炎5例报道并文献复习［J］. 疑难病杂志, 2017, 16(11): 1149-1151.
［18］Clara JA, Kalan SP, Oller KL. The enemy within: anti-NMDA receptor encephalitis［J］. Am J Med, 2016, 129(10): 154-158.
［19］Jeraiby M, Depincé-Berger A, Bossy V, et al. A case of anti-NMDA receptor encephalitis in a woman with a NMDA-R+, small cell lung carcinoma (SCLC) ［J］. Clin Immunol, 2016, 166(27): 96-99.
［20］Tang S, Alpert O. Management of psychiatric symptoms in pediatric anti-NMDA receptor encephalitis: Case report and systematic review［J］. Eur Psychiat, 2016, 33(19): 445-445.

[1]	何李华, 朱秀之, 江一舟. 三阴性乳腺癌免疫治疗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 842-853.
[2]	侯琼, 刘飞, 陈传荣. 免疫治疗联合抗血管生成药物+化疗在驱动基因阴性晚期非小细胞肺癌中的应用[J]. 中国临床药理学与治疗学, 2023, 28(7): 775-779.
[3]	王丹, 鄢晓丽, 张渊. 幽门螺杆菌感染影响胃癌免疫治疗的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(2): 228-234.
[4]	杨航, 陆方舟, 杨春, 朱伟. 氯胺酮拟精神症状及奖励机制的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(12): 1347-1353.
[5]	李玮, 胡佳丽, 王凯, 贺毅憬. 黑色素瘤免疫治疗的研究现状与展望[J]. 中国临床药理学与治疗学, 2021, 26(9): 1053-1064.
[6]	赵全铭，杨洋. 晚期三阴性乳腺癌的药物治疗进展[J]. 中国临床药理学与治疗学, 2020, 25(4): 475-480.
[7]	闫盼, 施剑飞, 李静, 王晟东, 王姝琪, 汪程鹏, 宋明芬. DRD2和5-HTR2A基因多态性及其交互作用对奥氮平治疗精神分裂症疗效的影响[J]. 中国临床药理学与治疗学, 2020, 25(10): 1131-1138.
[8]	常香香，韦中玲，郑幸媛，李慧敏，黄来全. 多发性骨髓瘤的治疗进展[J]. 中国临床药理学与治疗学, 2020, 25(1): 107-116.
[9]	张锴婷，陈乃涵. 生物药在肿瘤治疗领域的临床研究进展[J]. 中国临床药理学与治疗学, 2020, 25(1): 32-43.
[10]	万萍，刘亮，张萍，张忠东. 奥氮平在精神分裂症中的血清药物浓度/剂量比影响因素研究[J]. 中国临床药理学与治疗学, 2019, 24(9): 1024-1029.
[11]	蒙秋华，田婧，覃斐章，覃杨，董敏. PD-1/PD-L1通路抑制剂在消化系统肿瘤免疫治疗的研究进展[J]. 中国临床药理学与治疗学, 2018, 23(8): 942-948.
[12]	崔力军，潘鑫，朱洁琳，李建华. 帕利哌酮与奥氮平治疗首发精神分裂症患者的疗效观察[J]. 中国临床药理学与治疗学, 2017, 22(4): 466-470.
[13]	王韦力，廖萍，许标波，周成芳，谢商宸，沈冬亚，贺毅憬，Howard L. Mcleod. 肿瘤免疫检查点抑制剂个体化用药策略研究进展[J]. 中国临床药理学与治疗学, 2017, 22(2): 228-232.
[14]	杨何，张升，辛艳飞. 肿瘤免疫治疗研究进展[J]. 中国临床药理学与治疗学, 2016, 21(9): 1074-1080.
[15]	艾雄飞，杜丹玉，孙立，林森森，袁胜涛. 靶向肿瘤相关巨噬细胞的治疗进展及风险[J]. 中国临床药理学与治疗学, 2016, 21(6): 697-702.

低剂量奥氮平控制抗NMDAR脑炎精神症状的联系分析

Association analysis of low dose olanzapine in controlling mental symptoms of NMDAR encephalitis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价